论文部分内容阅读
目的研究糖皮质激素治疗对慢性阻塞性肺部疾病(COPD)患者下丘脑-垂体-甲状腺轴激素水平的影响。方法采用放射免疫法分别测定65例使用糖皮质激素治疗的COPD患者(COPD组)急性期和缓解期TT3、FT3、TT4、FT4、TSH水平,采用同样方法测定63例未使用糖皮质激素的其他肺部疾病患者(对照组)的血清TT3、FT3、TT4、FT4、TSH水平。结果 COPD组与对照组急性期比较,血清TT3(1.18±0.42)nmol/Lvs(1.29±0.45)nmol/L、FT3(3.68±0.76)pmol/Lvs(4.00±0.72)pmol/L、TT4(104.07±34.47)nmol/Lvs(109.30±33.73)nmol/L、FT4(13.71±3.12)pmol/Lvs(13.58±3.53)pmol/L及TSH(1.29±1.13mIU/L)vs(1.36±1.34mIU/L)水平差异均无显著性。两组患者急性期TT3、FT3均低于各自缓解期水平,差异有显著性(P<0.05),TT4、FT4及TSH急性期与缓解期相比,差异无显著性。结论 COPD急性期患者使用糖皮质激素治疗未进一步影响下丘脑-垂体-甲状腺轴功能。
Objective To investigate the effects of glucocorticoid on hypothalamus-pituitary-thyroid axis hormone in patients with chronic obstructive pulmonary disease (COPD). Methods The levels of TT3, FT3, TT4, FT4 and TSH in 65 patients with COPD (COPD group) treated with glucocorticoid were measured by radioimmunoassay in the acute and remission stages respectively. The other 63 patients without glucocorticoid Serum TT3, FT3, TT4, FT4, TSH levels in patients with lung disease (control group). Results The serum levels of TT3 (1.18 ± 0.42) nmol / Lvs (1.29 ± 0.45) nmol / L, FT3 (3.68 ± 0.76) pmol / Lvs (4.00 ± 0.72) pmol / L and TT4 ± 34.47nmol / L vs 109.3 ± 33.73 nmol / L, FT4,13.5 ± 3.53μmol / L and TSH (1.29 ± 1.13mIU / L) vs (1.36 ± 1.34mIU / L ) Level differences were not significant. TT3 and FT3 in the acute phase of both groups were lower than those in the remission stage (P <0.05). There was no significant difference between the acute phase of TT4, FT4 and TSH in remission stage. Conclusion The use of glucocorticoid in patients with acute COPD did not further affect the hypothalamic-pituitary-thyroid axis.